Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leveraging insights from cancer to improve tuberculosis therapy.
Datta M, Via LE, Dartois V, Xu L, Barry CE 3rd, Jain RK. Datta M, et al. Among authors: barry ce 3rd. Trends Mol Med. 2024 Aug 13:S1471-4914(24)00205-3. doi: 10.1016/j.molmed.2024.07.011. Online ahead of print. Trends Mol Med. 2024. PMID: 39142973 Free article. Review.
Distributable, metabolic PET reporting of tuberculosis.
Khan RMN, Ahn YM, Marriner GA, Via LE, D'Hooge F, Seo Lee S, Yang N, Basuli F, White AG, Tomko JA, Frye LJ, Scanga CA, Weiner DM, Sutphen ML, Schimel DM, Dayao E, Piazza MK, Gomez F, Dieckmann W, Herscovitch P, Mason NS, Swenson R, Kiesewetter DO, Backus KM, Geng Y, Raj R, Anthony DC, Flynn JL, Barry CE 3rd, Davis BG. Khan RMN, et al. Among authors: barry ce 3rd. Nat Commun. 2024 Jun 27;15(1):5239. doi: 10.1038/s41467-024-48691-6. Nat Commun. 2024. PMID: 38937448 Free PMC article.
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities.
Boshoff HIM, Young K, Ahn YM, Yadav VD, Crowley BM, Yang L, Su J, Oh S, Arora K, Andrews J, Manikkam M, Sutphin M, Smith AJ, Weiner DM, Piazza MK, Fleegle JD, Gomez F, Dayao EK, Prideaux B, Zimmerman M, Kaya F, Sarathy J, Tan VY, Via LE, Tschirret-Guth R, Lenaerts AJ, Robertson GT, Dartois V, Olsen DB, Barry CE 3rd. Boshoff HIM, et al. Among authors: barry ce 3rd. ACS Infect Dis. 2024 May 10;10(5):1679-1695. doi: 10.1021/acsinfecdis.4c00025. Epub 2024 Apr 6. ACS Infect Dis. 2024. PMID: 38581700
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits.
Datta M, Via LE, Dartois V, Weiner DM, Zimmerman M, Kaya F, Walker AM, Fleegle JD, Raplee ID, McNinch C, Zarodniuk M, Kamoun WS, Yue C, Kumar AS, Subudhi S, Xu L, Barry CE 3rd, Jain RK. Datta M, et al. Among authors: barry ce 3rd. Proc Natl Acad Sci U S A. 2024 Apr 2;121(14):e2321336121. doi: 10.1073/pnas.2321336121. Epub 2024 Mar 26. Proc Natl Acad Sci U S A. 2024. PMID: 38530888 Free PMC article.
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Diacon AH, Barry CE 3rd, Carlton A, Chen RY, Davies M, de Jager V, Fletcher K, Koh GCKW, Kontsevaya I, Heyckendorf J, Lange C, Reimann M, Penman SL, Scott R, Maher-Edwards G, Tiberi S, Vlasakakis G, Upton CM, Aguirre DB. Diacon AH, et al. Among authors: barry ce 3rd. Nat Med. 2024 Mar;30(3):896-904. doi: 10.1038/s41591-024-02829-7. Epub 2024 Feb 16. Nat Med. 2024. PMID: 38365949 Free PMC article. Clinical Trial.
278 results